Another new drug treatment for multiple sclerosis moves forward. A phase 3 trial of Teva Pharmaceutical's oral laquinimod for relapsing-remitting multiple sclerosis (RRMS) showed a modest reduction in relapse rates and lesions and a more substantial reduction in disability progression when compared with placebo. The study results were published March 15 in the New England Journal of Medicine.
The trial enrolled 1,106 RRMS patients in 24 countries. The volunteers were randomly assigned to receive a 0.6 mg daily dose of oral laquinimod or a placebo for 24 months.